FDA Drug Topics: Understanding Generic Narrow Therapeutic Index Drugs - November 1, 2022
FDA’s Division of Drug Information in the Center for Drug Evaluation and Research (CDER) is excited to present a series of educational webinars targeting the needs of all health care professionals and students, including physicians, physician assistants, nurses, pharmacists, and pharmacy technicians. Interact with FDA staff from a variety of divisions and learn more about the FDA and drug regulation!
On Tuesday, November 1, 2022, CDER's Office of Communication, Division of Drug Information (DDI) hosted a webinar titled: FDA Drug Topics: Understanding Generic Narrow Therapeutic Index Drugs. This webinar provided health care providers with information and knowledge on how to answer questions that patients may have about narrow therapeutic index (NTI) generic drugs, such as how the FDA recognizes the importance of bioequivalence in NTI generic drugs and has stricter standards for bioequivalence of NTI drugs than for other generic drugs. The presentation also gave providers information on FDA's post-market research efforts to ensure therapeutic equivalence of generic NTI drugs.
View Presentation Here: Understanding Generic Narrow Therapeutic Index Drugs
Download Presentation Slides: FDA Drug Topics: Understanding Generic Narrow Therapeutic Index Drugs (PDF - 1MB)
Activity Outline and Continuing Education Information
If you have never attended an Adobe Connect meeting before:
Test your connection: Adobe Connect Diagnostic Test
Get a quick overview: Discover Adobe Connect Solutions
Adobe, the Adobe logo, Acrobat and Adobe Connect are either registered trademarks or trademarks of Adobe Systems Incorporated in the United States and/or other countries.
Resources For You